Resmed Stock Price, News & Analysis

ResMed (NYSE: RMD) announced its plans to release third-quarter financial results for fiscal year 2023 on April 27, after market close. The company will host a webcast at 1:30 p.m. PDT to discuss the results and share additional forward-looking information. The event demonstrates ResMed's commitment to transparency with investors and stakeholders. Following the live webcast, a replay will be available on the company’s website, providing convenient access to the information shared. ResMed, known for its innovative digital health technologies and cloud-connected medical devices, serves over 140 countries, aiming to enhance healthcare delivery for chronic conditions.

ResMed (NYSE: RMD) announced that David Pendarvis, its chief administrative officer and global general counsel, will retire on June 30, 2023, after over 20 years with the company. He will transition to a consulting role until December 31, 2023. ResMed plans to conduct an internal search for his successor, aiming for a seamless transition. Amy Wakeham, currently Vice President of Corporate Communications & Investor Relations, has been appointed as the new Chief Communications and Investor Relations Officer, effective April 1, 2023. CEO Mick Farrell praised Pendarvis for his leadership during ResMed's transformation into a $30 billion global leader in digital health.

ResMed (NYSE: RMD) announced that Rob Douglas, president and COO, will participate in a fireside chat at the 2023 KeyBanc Life Sciences & MedTech Investor Forum on March 21, 2023, at approximately 3:45 p.m. EDT. The event will be accessible via webcast. Interested parties can find more information and access the live audio-only webcast by visiting ResMed Investor Relations. A replay will be available 24 hours after the event and will remain accessible for 90 days. ResMed focuses on innovative digital health technologies and cloud-connected medical devices for chronic diseases.

ResMed (NYSE: RMD) announced that Rob Douglas, the president and COO, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at approximately 11:20 a.m. EDT. The presentation will be accessible via a webcast, and interested parties can find more information and access the live stream on ResMed's investor relations website. A replay will be available approximately 24 hours after the event and can be accessed for 90 days. ResMed specializes in innovative solutions for chronic diseases, enhancing care with digital health technologies and cloud-connected medical devices across over 140 countries.

ResMed (NYSE: RMD) has appointed Mick Farrell as the new chair of the board, effective January 25, 2023. Farrell, who has been CEO since March 2013, succeeds Peter Farrell, who will transition to chair emeritus but remain on the board. Under Mick's leadership, ResMed's market capitalization surged from $6 billion to over $30 billion, achieving a total shareholder return of 507% over the past decade. The board believes combining the CEO and chair roles will enhance efficiency and align with practices of many S&P 500 peers. The company aims to positively impact 250 million lives by 2025.

ResMed reported a 16% year-over-year revenue growth for Q2 2023, totaling $1,033.7 million. This growth was driven by strong demand for sleep and respiratory care devices and an increase of 20% on a constant currency basis. Operating income also increased by 13%, while non-GAAP operating profit rose by 14%. The company achieved a diluted EPS of $1.53 and a non-GAAP diluted EPS of $1.66, reflecting a 13% increase from the previous year. ResMed completed the acquisition of MEDIFOX DAN, enhancing its Software-as-a-Service (SaaS) offerings in Europe. A quarterly cash dividend of $0.44 per share was declared, payable on March 16, 2023.